Adcentrx Therapeutics reports the initial dosing of a patient in the Phase 1a/b trial of ADRX-0706, an innovative ADC targeting Nectin-4, aimed to treat advanced solid tumors.

Kallyope, Inc. has commenced its Phase 2 experiment to assess K-757 and K-833.

A new research indicates that Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, elicits robust and long-lasting immunity in lab animals.

Takeda announced U.S. FDA approval for ENTYVIO®(vedolizumab) subcutaneous delivery as a maintenance treatment for moderate to severe ulcerative colitis in adults, after initial intravenous therapy.

Gamida Cell Ltd. has declared that the initial patient has been subjected to a stem cell transplantation procedure using Omisirge (omidubicel-onlv).

Abeona Therapeutics Inc. has reported that they've lodged a BLA with U.S. FDA with a request to endorse EB-101.

The US FDA approved AltruBio Inc.'s IND request, allowing Phase 2 clinical trials to start for its immune checkpoint booster, ALTB-268, for ulcerative colitis.

Intercept's principal drug is Ocaliva® (obeticholic acid), an FDA-approved farnesoid X receptor agonist in the United States and numerous other regions.

Gracell Biotechnologies Inc. has announced that the initial patient in the US has begun treatment in a Phase 1b/2 clinical trial for it's foremost candidate, GC012F, targeting patients with recurrent or resistant multiple myeloma.

Adverum Biotechnologies has released early findings on aflibercept protein activity from its ongoing Phase 2 LUNA study.

Two patients have been administered the initial dosage of SMART101, an allogeneic cell therapy created from donor mobilized peripheral blood stem cells which have been converted into T-cell progenitors utilizing the ProTcell treatment platform by Smart Immune.

Ionis declared encouraging preliminary findings from Phase 3 trial of Olezarsen in patients suffering from familial chylomicronemia syndrome.